Cargando…

Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases

The aim of this study was to determine the role of endothelin-1 (ET-1), a molecule involved in multiple vascular and fibrosing abnormalities, as a biomarker of interstitial lung disease (ILD), as well as its use for the differential diagnosis between idiopathic pulmonary fibrosis (IPF) and ILD assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pulito-Cueto, Verónica, Genre, Fernanda, López-Mejías, Raquel, Mora-Cuesta, Víctor Manuel, Iturbe-Fernández, David, Portilla, Virginia, Sebastián Mora-Gil, María, Ocejo-Vinyals, Javier Gonzalo, Gualillo, Oreste, Blanco, Ricardo, Corrales, Alfonso, Ferraz-Amaro, Iván, Castañeda, Santos, Cifrián Martínez, José Manuel, Atienza-Mateo, Belén, Remuzgo-Martínez, Sara, González-Gay, Miguel Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862125/
https://www.ncbi.nlm.nih.gov/pubmed/36674789
http://dx.doi.org/10.3390/ijms24021275
Descripción
Sumario:The aim of this study was to determine the role of endothelin-1 (ET-1), a molecule involved in multiple vascular and fibrosing abnormalities, as a biomarker of interstitial lung disease (ILD), as well as its use for the differential diagnosis between idiopathic pulmonary fibrosis (IPF) and ILD associated with autoimmune diseases (AD-ILD), using a large and well-defined cohort of patients with ILD. A total of 112 patients with IPF, 91 patients with AD-ILD (28 rheumatoid arthritis (RA), 26 systemic sclerosis, 20 idiopathic inflammatory myositis and 17 interstitial pneumonia with autoimmune features) and 44 healthy controls were included. ET-1 serum levels were determined by enzyme-linked immunosorbent assay. A significant increase in ET-1 levels was found in patients with IPF compared to controls. Likewise, AD-ILD patients also showed higher ET-1 levels than controls when the whole cohort was stratified by the type of AD. Similar ET-1 levels were found in IPF and AD-ILD patients, regardless of the underlying AD. Interestingly, increased ET-1 levels were correlated with worse lung function in IPF and RA-ILD patients. Our study supports that serum ET-1 may be useful as a biomarker of ILD, although it could not help in the differential diagnosis between IPF and AD-ILD. Moreover, ET-1 levels may be associated with ILD severity.